Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof
Reexamination Certificate
1998-06-04
2009-10-13
Yaen, Christopher H (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Cancer cell or component thereof
C424S184100
Reexamination Certificate
active
07601359
ABSTRACT:
The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. The effective amounts of the complex are in the range of 10-600 micrograms for complexes comprising hsp70, 50-1000 micrograms for hsp90, and 10-600 micrograms for gp96. The invention also provides a method for measuring tumor rejection in vivo in an individual, preferably a human, comprising measuring the generation by the individual of MHC Class I-restricted CD8+ cytotoxic T lymphocytes specific to the tumor. Methods of purifying hsp70-peptide complexes are also provided.
REFERENCES:
patent: 4690915 (1987-09-01), Rosenberg
patent: 4963354 (1990-10-01), Shepard et al.
patent: 5188964 (1993-02-01), McGuire et al.
patent: 5232833 (1993-08-01), Sanders et al.
patent: 5348945 (1994-09-01), Berberian et al.
patent: 5747332 (1998-05-01), Wallen et al.
patent: 5750119 (1998-05-01), Srivastava
patent: 5830464 (1998-11-01), Srivastava
patent: 5837251 (1998-11-01), Srivastava
patent: 5935576 (1999-08-01), Srivastava
patent: 5948646 (1999-09-01), Srivastava
patent: 5961979 (1999-10-01), Srivastava
patent: 5981706 (1999-11-01), Wallen et al.
patent: 5985270 (1999-11-01), Srivastava
patent: 5997873 (1999-12-01), Srivastava
patent: 6007821 (1999-12-01), Srivastava et al.
patent: 6017540 (2000-01-01), Srivastava et al.
patent: 6017544 (2000-01-01), Srivastava
patent: 6030618 (2000-02-01), Srivastava
patent: 6048530 (2000-04-01), Srivastava
patent: 6066716 (2000-05-01), Wallen et al.
patent: 6130087 (2000-10-01), Srivastava et al.
patent: 6136315 (2000-10-01), Srivastava
patent: 6139841 (2000-10-01), Srivastava
patent: 6143299 (2000-11-01), Srivastava
patent: 6156302 (2000-12-01), Srivastava
patent: 6162436 (2000-12-01), Srivastava
patent: 6168793 (2001-01-01), Srivastava
patent: 6322790 (2001-11-01), Srivastava
patent: 6433141 (2002-08-01), Wallen et al.
patent: 6451316 (2002-09-01), Srivastava
patent: 6475490 (2002-11-01), Srivastava et al.
patent: 6713608 (2004-03-01), Wallen et al.
patent: 2004/0047876 (2004-03-01), Srivastava
patent: 2004/0143105 (2004-07-01), Wallen et al.
patent: 196 02 985 (1997-07-01), None
patent: 2 251 186 (1992-07-01), None
patent: 07-504423 (1995-05-01), None
patent: 10-501520 (1998-02-01), None
patent: 2000-507083 (2000-06-01), None
patent: WO 89/12455 (1989-12-01), None
patent: WO 90/02564 (1990-03-01), None
patent: WO 91/15572 (1991-10-01), None
patent: WO 92/01717 (1992-02-01), None
patent: WO 92/08484 (1992-05-01), None
patent: WO 92/08488 (1992-05-01), None
patent: WO 93/14118 (1993-07-01), None
patent: WO 93/17712 (1993-09-01), None
patent: WO 93/18146 (1993-09-01), None
patent: WO 93/18147 (1993-09-01), None
patent: WO 93/18150 (1993-09-01), None
patent: WO 93/21529 (1993-10-01), None
patent: WO 93/24136 (1993-12-01), None
patent: WO 94/03208 (1994-02-01), None
patent: WO 94/04676 (1994-03-01), None
patent: WO 94/11513 (1994-05-01), None
patent: WO 94/29459 (1994-12-01), None
patent: WO 95/24923 (1995-09-01), None
patent: WO 96/10411 (1996-04-01), None
patent: WO 97/06685 (1997-02-01), None
patent: WO 97/06821 (1997-02-01), None
patent: WO 97/06828 (1997-02-01), None
patent: WO 97/10001 (1997-03-01), None
patent: WO 97/10002 (1997-03-01), None
patent: WO 97/26910 (1997-07-01), None
patent: WO 98/12208 (1998-03-01), None
patent: WO 98/34641 (1998-08-01), None
patent: WO 99/29182 (1999-06-01), None
Clarke et al Mol. Cell. Biol. vol. 8(3), p. 1206-15, 1988.
Sherman et al Journ. Bacteriol. vol. 173(22) p. 7249-56, 1991.
Palleros et al (J. Biol. Chem. May 1994; 269(18):13107-13114).
Aldovini et al. (1992) “The New Vaccines”,Technology Reviewpp. 24-31.
Barrios et al. (1992) “Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines that can circumvent the need for adjuvants andBacillus calmetteGuérin priming”,Eur. J. Immunol. 22:1365-1372.
Basombrio (1970) “Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene”,The Institute for Cancer Research30:2458-2462.
Blachere et al. (1993) “Heat Shock Protein Vaccines Against Cancer,”Journal of Immunotherapy14:352-356.
Blachere and Srivastava (1993) “Immunization with GP96 heat shock proteins isolated from tumors or influenza virus infected cells elicits MHC-restricted, antigen-specific cytotoxic T lymphocytes against the corresponding cells”,J. Cellular Biochem. Keystone SymposiaNZ502, p. 124.
Boon “Toward a genetic analysis of tumor rejection antigens”,Advances in Cancer Research58:177-210.
Cohen (1993) “Cancer Vaccines Get A Shot In The Arm”,Science262:841-843.
Craig (1993) “Chaperones: Helpers Along the Pathways to Protein Folding”,Science260:1902-1904.
Elliott et al. (1990) “Naturally Processed Peptides”,Nature348:195-197.
Falk et al. (1991) “Allele-specific Motifs Revealed by Sequencing of Self-peptides Eluted from MHC Molecules”,Nature351:290-296.
Falk et al. (1990) “Cellular Peptide Composition Governed by Major Histocompatibility Complex Class I Molecules”,Nature348:248-251.
Fadweg and Srivastava (Jun. 13, 1996) “Evidence for biochemical heterogeneity of gp96 heat shock protein/tumor rejection antigen”, Mount Sinai School of Medicine NZ 206, p. 108.
Flynn et al. (1989) “Peptide binding and release by proteins implicated as catalysts of protein assembly”,Science245:385-390.
Flynn et al. (1991) “Peptide-binding Specificity of the Molecular Chaperone BiP”,Nature353:726-730.
Franklin (1993) “Making vaccines fit the cancer”,New Scientist140:17.
Gething et al. (1992) “Protein Folding in the Cell”,Nature355:33-45.
Globerson and Feldman (1964) “Antigenic specificity of benzo[a]pyrene-induced sarcomas”,Journal of the National Cancer Institute32(6):1229-1242.
Jakob et al. (1993) “Small Heat Shock Proteins Are Molecular Chaperones”,J. Biol. Chem. 268:1517-1520.
Jardetzky et al. (1991) “Identification of Self Peptides Bound to Purified HLA-B27”,Nature353:326-329.
Lakey et al (1987) “Identification of a peptide binding protein that plays a role in antigen presentation”,Proc. Natl. Acad. Sci. USA84:1659-1663.
Lanzavecchia (1993) “Identifying Strategies for Immune Intervention”,Science260:937-944.
Lévy (1991) “ATP is Required for In Vitro Assemlby of MHC Class I Antigens but Not for Transfer of Peptides across the ER Membrane”,Cell67:265-274.
Li and Srivastava (1993) “Tumor rejection antigen gp96/grp94 is an ATPase: Implications for protein folding and antigen presentation”,EMBO J. 12(8):3143-3151.
Lindquist and Craig (1988) “The heat-shock proteins”,Ann. Rev. Genet. 22:631-677.
Luescher et al. (1991) “Specific Binding of Antigenic Peptides to Cell-associated MHC Class I Molecules”,Nature351:72-77.
Lukacs et al. (1991) “Tumor cells transfected with a bacterial heat-shock gene lose tumorigenicity and induce protection against tumors”,J. Exp. Med. 178:343-348.
Lussow et al. (1991) “Mycobacterial heat-shock proteins as carrier molecules”,Eur. J. Immunol. 21:2297-2302.
Madden et al. (1991) “The Structure of HLA-B27 Reveals Nonamer Self-peptides Bound i
Fordham University
Jones Day
Yaen Christopher H
LandOfFree
Compositions and methods for the prevention and treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the prevention and treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the prevention and treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4070149